Basic Stats
| CIK | 1651944 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DermTech, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 18, 2024 |
DERMTECH FILES FOR VOLUNTARY CHAPTER 11 PROTECTION Exhibit 99.1 DERMTECH FILES FOR VOLUNTARY CHAPTER 11 PROTECTION SAN DIEGO – June 18, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company’s s |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 14, 2024 |
Exhibit 99.1 DERMTECH REPORTS FIRST-QUARTER 2024 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year -Test revenue increased 7 percent versus the first quarter of 2023 SAN DIEGO – May 14, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics techno |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 26, 2024 |
EX-99.1 2 tm2412585d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but n |
|
| April 26, 2024 |
DMTK / DermTech, Inc. / VAN HERK INVESTMENTS B.V. - SC 13G Passive Investment SC 13G 1 tm2412585d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DermTech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 24984K105 (CUSIP Number) April 19, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38118 DERMTECH, INC. (Exact name of registrant a |
|
| April 18, 2024 |
DERMTECH TO EXPLORE STRATEGIC ALTERNATIVES AND IMPLEMENT RESTRUCTURING PLAN Exhibit 99.1 DERMTECH TO EXPLORE STRATEGIC ALTERNATIVES AND IMPLEMENT RESTRUCTURING PLAN SAN DIEGO – April 18, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives |
|
| April 18, 2024 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) DermTech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price (4) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 REGISTRATION NO. |
|
| February 29, 2024 |
Exhibit 4.12 DESCRIPTION OF DERMTECH, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, DermTech, Inc. (the “Company” or “we”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, $0.0001 par value per share, or Common Stock. Our Common Stock is listed on The Nasda |
|
| February 29, 2024 |
Exhibit 99.1 DERMTECH REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year -Test revenue increased 38 percent versus the fourth quarter of 2022 -Estimated cash runway into the first quarter of 2025 SAN DIEGO – February 29, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precis |
|
| February 29, 2024 |
, 2024, by and between the Company and Claudia Ibarra Exhibit 10.45 January 31, 2024 PERSONAL AND CONFIDENTIAL BY EMAIL Claudia Ibarra Dear Claudia: The purpose of this separation agreement (the “Agreement”) is to advise you that your last day of employment with DermTech, Inc. (the “Company”) will be February 2, 2024 (“the Termination Date”). This letter outlines the terms of certain benefits and payments to you in connection with your termination. 1 |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38118 DERMTECH, INC. (Exact name of registrant as specified in its c |
|
| February 8, 2024 |
DMTK / DermTech, Inc. / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment SC 13G/A 1 tm245614d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DermTech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 24984K105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 8, 2024 |
EX-99.1 2 tm245614d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but no |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 31, 2024 |
Exhibit 99.1 DERMTECH ANNOUNCES ADDITIONAL RESTRUCTURING ACTIONS TO FOCUS ON REVENUE GROWTH AND STREAMLINE OPERATIONS –Ongoing emphasis on growing revenue for the DermTech Melanoma Test (DMT) –Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring actions SAN DIEGO – January 31, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the |
|
| December 12, 2023 |
DMTK / DermTech Inc / RTW INVESTMENTS, LP - DERMTECH, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4) DermTech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 24984K105 (CUSIP Number) Eleazer K |
|
| November 2, 2023 |
DermTech, Inc. Clawback Policy Exhibit 10.2 DERMTECH, INC. CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of DermTech, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted thi |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 2, 2023 |
Exhibit 99.1 DERMTECH REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year -Test revenue increased 8 percent versus the third quarter of 2022 -Cash runway into the first quarter of 2025 SAN DIEGO – November 2, 2023 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatolog |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| September 11, 2023 |
Offer Letter, dated September 5, 2023, by and between the Company and Mark Aguillard Exhibit 10.1 September 5, 2023 Mark Aguillard [email protected] RE: EMPLOYMENT OFFER Dear Mark, We are thrilled to offer you the role of Chief Commercial Officer at DermTech, Inc. (the “Company”). At DermTech, we are on a mission to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. We are so glad to have you join the team |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File |
|
| September 11, 2023 |
DERMTECH APPOINTS MARK AGUILLARD AS CHIEF COMMERCIAL OFFICER Exhibit 99.1 DERMTECH APPOINTS MARK AGUILLARD AS CHIEF COMMERCIAL OFFICER SAN DIEGO – September 11, 2023 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall |
|
| August 7, 2023 |
As filed with the Securities and Exchange Commission on August 7, 2023 As filed with the Securities and Exchange Commission on August 7, 2023 REGISTRATION NO. |
|
| August 7, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) DermTech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0 |
|
| August 3, 2023 |
Amended and Restated Certificate of Incorporation of the Company, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONSTELLATION ALPHA CAPITAL CORP. (originally incorporated on August 27, 2019 under the name Constellation Alpha Capital Corp.) FIRST: The name of the Corporation is DermTech, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Ca |
|
| August 3, 2023 |
Exhibit 99.1 DERMTECH REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS -Covered lives increased to 133 million -Average selling price and test revenue grew sequentially -Cash runway into the first quarter of 2025 SAN DIEGO – August 3, 2023 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (C |
|
| July 13, 2023 |
Separation Agreement, by and between the Company and Todd Wood, dated June 26, 2023 Exhibit 10.1 June 26, 2023 PERSONAL AND CONFIDENTIAL BY EMAIL Todd Wood Dear Todd: The purpose of this separation agreement (the “Agreement”) is to advise you that your last day of employment with DermTech, Inc. (the “Company”) will be July 3, 2023 (“the Termination Date”). This letter outlines the terms of certain benefits and payments to you in connection with your termination. 1.Terms of Benefi |
|
| June 28, 2023 |
Exhibit 99.1 DERMTECH ANNOUNCES RESTRUCTURING TO PRIORITIZE GROWTH OPPORTUNITIES AND STREAMLINE OPERATIONS –Strategic focus on growing revenue for the DermTech Melanoma Test (DMT) –Annualized cost reduction of between $25 million and $30 million –Cash runway extended into the first quarter of 2025 SAN DIEGO – June 28, 2023 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in prec |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 16, 2023 |
DMTK / DermTech Inc / VAN HERK INVESTMENTS B.V. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DermTech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 24984K105 (CUSIP Number) June 7, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| June 16, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 5, 2023 |
Exhibit 3.1 THIRD CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMTECH, INC. DermTech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The Amended and Restated Certificate of Incorporation of the Corporation, as amended, is hereby further amended by deleting the first par |
|
| June 5, 2023 |
DermTech, Inc. 2020 Equity Incentive Plan, as amended and restated on May 31, 2023 Exhibit 10.1 DERMTECH, INC. 2020 EQUITY INCENTIVE PLAN (AS AMENDED AND RESTATED ON MAY 31, 2023) 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this DermTech, Inc. 2020 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committe |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2023 |
Employment Agreement, dated May 6, 2023 by and between the Company and Bret Christensen Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”) by and between DermTech, Inc. (the “Company”), a Delaware corporation, and Bret Christensen (“Executive”). References below to the “Company” shall include its subsidiaries and affiliates when applicable. 1.Roles and Duties. (a)Role. Subject to the terms and condition |
|
| May 9, 2023 |
Second Amended and Restated 2022 Inducement Equity Incentive Plan Exhibit 10.2 DERMTECH, INC. SECOND AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this DermTech, Inc. Second Amended and Restated 2022 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power |
|
| May 9, 2023 |
DERMTECH APPOINTS BRET CHRISTENSEN AS NEW PRESIDENT AND CEO Exhibit 99.1 DERMTECH APPOINTS BRET CHRISTENSEN AS NEW PRESIDENT AND CEO SAN DIEGO – May 9, 2023 – DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Bret Christensen, previously chief commercial officer of Insulet, as president, chief executive officer and a member of t |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2023 |
Transition Agreement, dated March 1, 2023, by and between the Company and John Dobak Exhibit 10.1 DermTech, Inc. March 1, 2023 PERSONAL AND CONFIDENTIAL BY HAND John Dobak, M.D. Dear John: The purpose of this letter (the “Transition Agreement”) is to set forth our agreements concerning your anticipated transition from DermTech, Inc. (the “Company”). 1.Employment through Transition Period. You and the Company have agreed that you will remain employed as the Company’s President and |
|
| May 4, 2023 |
Exhibit 99.1 DERMTECH REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS -Covered lives increased to 126 million -Cash runway through the third quarter of 2024 SAN DIEGO – May 4, 2023 – DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial results. “In the last few m |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defini |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 3, 2023 |
As filed with the Securities and Exchange Commission on March 3, 2023 As filed with the Securities and Exchange Commission on March 3, 2023 REGISTRATION NO. |
|
| March 3, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) DermTech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(4) Maximum Aggregate Offering Price (4) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38118 DERMTECH, INC. (Exact name of registrant as |
|
| March 2, 2023 |
Exhibit 21.1 DermTech, Inc. Subsidiaries of the Registrant Subsidiary Jurisdiction of Incorporation DermTech Operations, Inc. Delaware |
|
| March 2, 2023 |
Exhibit 99.1 DERMTECH REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS; COMPANY ANNOUNCES CEO TRANSITION PLAN - Covered lives increased from 91 million to 124 million and cash runway through the third quarter of 2024 - Dr. John Dobak will continue to serve as CEO until a successor is appointed - Board initiates comprehensive CEO search LA JOLLA, Calif. – March 2, 2023 – DermTech, Inc. ( |
|
| March 2, 2023 |
2023 Corporate Bonus Plan of the Company Exhibit 10.22 2023 Corporate Bonus Plan 1.The DermTech, Inc. (“DermTech” or the “Company”) Corporate Bonus Plan (the “Bonus Plan”) should be simple to understand and incentivize eligible employees to achieve corporate goals which are in the best interests of stakeholders. 2.The Bonus Plan is split into first half (“1H”) and second half (“2H”) plans, with goals to be achieved during that set time p |
|
| February 14, 2023 |
DMTK / DermTech Inc / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO OFFICE LEASE This THIRD AMENDMENT TO OFFICE LEASE ("Third Amendment") is made and entered into as of October 7, 2022 (the ?Effective Date?), by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and DERMTECH, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Tenant are parties to the Office Lease dated July 1, 2021 |
|
| November 8, 2022 |
DMTK / DermTech Inc / RTW INVESTMENTS, LP - DERMTECH, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3) DermTech, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 24984K105 (CUSIP Number) Eleazer K |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 3, 2022 |
DERMTECH REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS Exhibit 99.1 DERMTECH REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS LA JOLLA, Calif. – November 3, 2022 – DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its third-quarter 2022 financial results. “We achieved meaningful year-over-year billable sample volume growth, but sequential growth w |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| November 3, 2022 |
DermTech, Inc. Amended and Restated 2020 Employee Stock Purchase Plan Exhibit 10.3 DermTech, Inc. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN (As amended August 9, 2022) The following constitute the provisions of the 2020 Employee Stock Purchase Plan (the "Plan") of DermTech, Inc. (the "Company"). 1.Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company |
|
| September 16, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) DermTech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| September 16, 2022 |
As filed with the Securities and Exchange Commission on September 16, 2022 As filed with the Securities and Exchange Commission on September 16, 2022 REGISTRATION NO. |
|
| September 16, 2022 |
DermTech, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan Exhibit 99.1 DERMTECH, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN (Adopted by the Board of Directors on September 1, 2022) 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this DermTech, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board o |
|
| August 17, 2022 |
Filed pursuant to Rule 424(b)5 Registration No. 333-266650 PROSPECTUS SUPPLEMENT (To Prospectus dated August 17, 2022) $75,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales ag |
|
| August 15, 2022 |
DERMTECH, INC. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 DERMTECH, INC. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 August 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE: DermTech, Inc. Registration Statement on Form S-3 Filed August 8, 2022 File No. 333-266650 Request for Acceleration Ladies and Gentlemen: With respect |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| August 8, 2022 |
Exhibit 10.01 FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE ("First Amendment") is made and entered into as of April 22, 2022 (the ?Effective Date?), by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and DERMTECH, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Tenant are parties to the Office Lease dated July 1, 2021 |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 8, 2022 |
Exhibit 10.2 SECOND AMENDMENT TO OFFICE LEASE This SECOND AMENDMENT TO OFFICE LEASE ("Second Amendment") is made and entered into as of April 22, 2022 (the ?Effective Date?), by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and DERMTECH, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Tenant are parties to the Office Lease dated July 1, 20 |
|
| August 8, 2022 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) DermTech, Inc. (Exact name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price ( |
|
| August 8, 2022 |
Sales Agreement, dated August 8, 2022, by and between the Company and Cowen EX-1.2 3 exhibit12tos-3xsalesagree.htm EX-1.2 Exhibit 1.2 DERMTECH, INC. $75,000,000 SALES AGREEMENT August 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: DermTech, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees |
|
| August 8, 2022 |
Second Amended and Restated Non-Employee Director Compensation Policy DermTech, Inc. Exhibit 10.3 Second Amended and Restated Non-Employee Director Compensation Policy DermTech, Inc. The Board of Directors of DermTech, Inc. (the ?Company?) has approved the following Second Amended and Restated Non-Employee Director Compensation Policy (this ?Policy?), which establishes compensation to be paid to non-employee directors of the Company, effective as of July 18, 2022 (the ?Effective T |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| August 8, 2022 |
DERMTECH REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS; COMPANY UPDATES FULL-YEAR 2022 OUTLOOK Exhibit 99.1 DERMTECH REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS; COMPANY UPDATES FULL-YEAR 2022 OUTLOOK LA JOLLA, Calif. ? August 8, 2022 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech? or the ?Company?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its second-quarter 2022 financial results and updated its full-year 2022 outlook. ?We continued |
|
| July 18, 2022 |
DERMTECH APPOINTS TWO NEW BOARD MEMBERS Exhibit 99.1 DERMTECH APPOINTS TWO NEW BOARD MEMBERS LA JOLLA, Calif. ? July 18, 2022 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech? or the ?Company?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company?s board of directors, effective July 18,2022. These appointments expan |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 31, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 3, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 3, 2022 |
DERMTECH REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS; COMPANY AFFIRMS FULL-YEAR 2022 OUTLOOK Exhibit 99.1 DERMTECH REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS; COMPANY AFFIRMS FULL-YEAR 2022 OUTLOOK - Record billable sample volume and assay revenue LA JOLLA, Calif. ? May 3, 2022 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech? or the ?Company?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2022 financial results and affir |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 11, 2022 |
EX-FILING FEES 7 dmtk-exfilingfees7.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) DermTech, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(5) Maximum Aggregate Offering Price Fee Rate Amount of Registratio |
|
| March 11, 2022 |
Exhibit 99.3 Restricted Stock Unit No. [] DERMTECH, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the DermTech, Inc. 2022 Inducement Equity Incentive Plan 1.Name and Address of Participant: 2.Grant Date: 3.Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 REGISTRATION NO. |
|
| March 11, 2022 |
2022 Inducement Equity Incentive Plan Exhibit 99.1 DERMTECH, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this DermTech, Inc. 2022 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case th |
|
| March 11, 2022 |
Exhibit 99.2 Option No. DERMTECH, INC. Stock Option Grant Notice Stock Option Grant under the Company?s 2022 Inducement Equity Incentive Plan 1.Name and Address of Participant: 2.Date of Option Grant: 3.Type of Grant:Non-Qualified Option 4.Maximum Number of Shares for which this Option is exercisable: 5.Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesti |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K 1GG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38118 DERMTECH, INC. (Exact name of registrant as specified in i |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-38118 (Check one): ? Form 10?K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N?SAR ? Form N?CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report |
|
| March 1, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 1, 2022 |
DermTech Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 DermTech Reports Fourth Quarter and Full Year 2021 Financial Results LA JOLLA, Calif. ? March 1, 2022 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of and for the quarter and fiscal year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highlights ? Billable |
|
| February 14, 2022 |
DMTK / DermTech Inc / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 9, 2021 |
DermTech Reports Third Quarter 2021 Financial Results Exhibit 99.1 DermTech Reports Third Quarter 2021 Financial Results LA JOLLA, Calif. ? November 9, 2021 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results for the quarter ended September 30, 2021. Third Quarter 2021 Highlights ? Billable sample volume of approximately 11,720 for |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| November 9, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 4, 2021 |
DermTech Reports Second Quarter 2021 Financial Results Exhibit 99.1 DermTech Reports Second Quarter 2021 Financial Results LA JOLLA, Calif. ? August 4, 2021 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results for the quarter ended June 30, 2021. Second Quarter 2021 Highlights ? Billable sample volume of approximately 11,750 for the |
|
| August 4, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| July 7, 2021 |
Office Lease, dated July 1, 2021, by and between the Company and Kilroy Realty, L.P. Exhibit 10.1 DEL MAR CORPORATE CENTRE II OFFICE LEASE This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and DERMTECH, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTI |
|
| July 7, 2021 |
8-K 1 dmtk-8k20210701.htm 8-K - DEL MAR OFFICE LEASE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other j |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 2, 2021 |
Resignation Letter, dated June 30, 2021, by and between the Company and Scott Pancoast Exhibit 10.1 June 30, 2021 PERSONAL AND CONFIDENTIAL Scott Pancoast Re: Resignation Agreement Dear Scott: The purpose of this letter agreement (the ?Agreement?) is to document the terms of your voluntary resignation from the Board of Directors (the ?Board?) of DermTech, Inc. (the ?Company?), and any subcommittees of the Board, which resignation will be effective as of the date you sign this Agreem |
|
| May 27, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 25, 2021 |
As filed with the Securities and Exchange Commission on May 25, 2021 As filed with the Securities and Exchange Commission on May 25, 2021 REGISTRATION NO. |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| May 13, 2021 |
DermTech Reports First Quarter 2021 Financial Results Exhibit 99.1 DermTech Reports First Quarter 2021 Financial Results LA JOLLA, Calif. ? May 13, 2021 ? DermTech, Inc. (NASDAQ: DMTK) (?DermTech?), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results for the quarter ended March 31, 2021. First Quarter 2021 Highlights ? Billable sample volume of approximately 9,400 for the first quarter |
|
| May 13, 2021 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.3 Amended and Restated Non-Employee Director Compensation Policy DermTech, Inc. The Board of Directors of DermTech, Inc. (the ?Company?) has approved the following Amended and Restated Non-Employee Director Compensation Policy (this ?Policy?), which establishes compensation to be paid to non-employee directors of the Company, effective as of March 28, 2021 (the ?Effective Time?), to pro |
|
| May 13, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 13, 2021 |
Form of Participation Agreement under the DermTech, Inc. Change in Control and Severance Plan Exhibit 10.2 PARTICIPATION AGREEMENT UNDER THE DERMTECH, INC. CHANGE IN CONTROL AND SEVERANCE PLAN This Participation Agreement by and between [?] (the ?Participant?) and DermTech, Inc., a Delaware corporation (the ?Company?), incorporates by reference and is governed by the DermTech, Inc. Change in Control and Severance Plan. The Participant hereby agrees and consents to the terms and conditions |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 1, 2021 |
DermTech, Inc. Change in Control and Severance Plan Exhibit 10.1 DermTech, Inc. CHANGE IN CONTROL AND SEVERANCE PLAN Article 1. Introduction The Board of Directors (the ?Board?) of DermTech, Inc., a Delaware corporation (?DermTech? or the ?Company?), considers the maintenance of a sound management to be essential to protecting and enhancing the best interests of the Company and its stockholders. In this connection, the Company recognizes that the p |
|
| March 5, 2021 |
Offer of Employment Letter, dated October 14, 2020, from the Company to Ray Akhavan Exhibit 10.28 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 Direct: 858.450.4222 Fax: 858.200.3877 www.dermtech.com October 14, 2020 Ray Akhavan RE: EMPLOYMENT OFFER Dear Ray, DermTech, Inc. (the ?Company?) is pleased to offer you employment as General Counsel and Chief Compliance Officer. You will report directly to John Dobak, Chief Executive Officer, at the Company?s facilities in Sa |
|
| March 5, 2021 |
Exhibit 4.12 DESCRIPTION OF DERMTECH, INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, DermTech, Inc. (the ?Company? or ?we?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, $0.0001 par value per share, or Common Stock. Our Common Stock is listed on The Nasda |
|
| March 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38118 DERMTECH, INC. (Exact name of registrant as |
|
| March 4, 2021 |
DermTech Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 DermTech Reports Fourth Quarter and Full Year 2020 Financial Results LA JOLLA, Calif. – March 4, 2021 – DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results for the quarter and year ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Highlights • Billable sample |
|
| March 4, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) DERMTECH, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 24984K105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Stateme |
|
| February 10, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) DERMTECH, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 24984K105 (CUSIP Number) January 31, 2021 (Date of Event Which Requires Filing of this Stateme |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* DERMTECH, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 24984K105 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong 40 10th Street, Floor 7, New York, New York 10014 (Name, Address and Telephone Number of Person Authorized to Rec |
|
| January 7, 2021 |
DermTech Announces Pricing of Public Offering of Common Stock Exhibit 99.1 DermTech Announces Pricing of Public Offering of Common Stock LA JOLLA, Calif. — (BUSINESS WIRE) — January 7, 2021 — DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the |
|
| January 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 7, 2021 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-248642 PROSPECTUS SUPPLEMENT (To Prospectus dated September 17, 2020) 4,237,288 Shares Common Stock We are offering 4,237,288 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “DMTK.” On January 6, 2021, the last reported sale price of our common stock on Nasdaq was |
|
| January 7, 2021 |
106823793v.5 Exhibit 1.1 4,237,288 Shares DERMTECH, INC. Common Stock UNDERWRITING AGREEMENT January 6, 2021 Cowen and Company, LLC William Blair & Company, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: 1.Introd |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 6, 2021 |
DermTech Announces Proposed Public Offering of Common Stock Exhibit 99.1 DermTech Announces Proposed Public Offering of Common Stock LA JOLLA, Calif. — (BUSINESS WIRE) — January 6, 2021 — DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, DermTech int |
|
| January 6, 2021 |
SUBJECT TO COMPLETION, DATED JANUARY 6, 2021 Filed pursuant to Rule 424(b)(5) Registration No. 333-248642 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| December 11, 2020 |
Corporate Presentation Q4 2020 COPYRIGHT © 2020 DERMTECH. ALL RIGHTS RESERVED. Exhibit 99.1 This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate |
|
| December 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K - UPDATED CORPORATE PRESENTATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 12, 2020 |
7,583,120 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS 7,583,120 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 7,583,120 shares of DermTech, Inc., or the Company, common stock, $0.0001 par value per share, or the common stock, as follows: (i) an aggregate of up to 7,533,370 shares of common stock held by parti |
|
| November 12, 2020 |
4,962,980 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS 4,962,980 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 4,962,980 shares of DermTech, Inc., or the Company, common stock, $0.0001 par value per share, or the common stock, as follows: (i) an aggregate of up to 4,593,668 shares of common stock issued in con |
|
| November 10, 2020 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-248642 PROSPECTUS SUPPLEMENT (To Prospectus dated September 17, 2020) $50,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sal |
|
| November 10, 2020 |
DermTech Reports Third Quarter 2020 Financial Results Exhibit 99.1 DermTech Reports Third Quarter 2020 Financial Results LA JOLLA, Calif. – November 10, 2020 – DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results as of and for the quarter ended September 30, 2020. Third Quarter Highlights • Assay revenues of $1.2 million for the third |
|
| November 10, 2020 |
Sales Agreement, dated November 10, 2020, by and between the Company and Cowen and Company, LLC Exhibit 1.1 DERMTECH, INC. $50,000,000 SALES AGREEMENT November 10, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: DermTech, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| November 10, 2020 |
Amended and Restated Certificate of Incorporation of the Company, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONSTELLATION ALPHA CAPITAL CORP. (originally incorporated on August 27, 2019 under the name Constellation Alpha Capital Corp.) FIRST: The name of the Corporation is DermTech, Inc. SECOND: The address of the Corporation?s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Ca |
|
| November 5, 2020 |
As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 5, 2020 |
As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| September 17, 2020 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-248657 PROSPECTUS 87,790 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 87,790 shares of DermTech, Inc., or the Company, common stock, $0.0001 par value per share, or the common stock, by the selling stockholders. The shares of common stock were issued to the selling stockho |
|
| September 15, 2020 |
DERMTECH, iNC. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 September 15, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE: DermTech, Inc. Registration Statement on Form S-3 Filed September 8, 2020 File No. 333-248657 Request for Acceleration Ladies and Gentlemen: With re |
|
| September 15, 2020 |
DERMTECH, iNC. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 September 15, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE: DermTech, Inc. Registration Statement on Form S-3 Filed September 8, 2020 File No. 333-248642 Request for Acceleration Ladies and Gentlemen: With re |
|
| September 10, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 10 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 10 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, co |
|
| September 10, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated May 11, 2020 6,627,685 Shares of Common Stock This prospectus supplement No. 6 supplements the prospectus dated May 11, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc., or the Company, common stock, |
|
| September 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 10, 2020 |
Certificate of Elimination of Series A Convertible Preferred Stock of the Company Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF DERMTECH, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware DermTech, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. That, pursuant to S |
|
| September 10, 2020 |
Certificate of Elimination of Series B‑2 Convertible Preferred Stock of the Company Exhibit 3.3 CERTIFICATE OF ELIMINATION OF SERIES B‑2 CONVERTIBLE PREFERRED STOCK OF DERMTECH, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware DermTech, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. That, pursuant to |
|
| September 10, 2020 |
Certificate of Elimination of Series B‑1 Convertible Preferred Stock of the Company Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES B-1 CONVERTIBLE PREFERRED STOCK OF DERMTECH, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware DermTech, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 151(g) of the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. That, pursuant to |
|
| September 8, 2020 |
As filed with the Securities and Exchange Commission on September 8, 2020 Registration No. |
|
| September 8, 2020 |
Exhibit 4.4 DERMTECH, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) 5.0 |
|
| September 8, 2020 |
As filed with the Securities and Exchange Commission on September 8, 2020 Registration No. |
|
| September 8, 2020 |
Form of Subordinated Indenture Exhibit 4.5 DERMTECH, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04 |
|
| August 14, 2020 |
- 8-K - FARALLON PREFERRED SHARE CONVERSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 14, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 9 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 9 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| August 14, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated May 11, 2020 6,627,685 Shares of Common Stock This prospectus supplement No. 5 supplements the prospectus dated May 11, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc., or the Company, common stock, |
|
| August 5, 2020 |
Exhibit 10.5 AMENDMENT NUMBER 2 TO THE DEFERRED UNDERWRITING FEE ASSIGNMENT AGREEMENT Cowen and Company, LLC As Representative of the several Underwriters c/o Cowen and Company, LLC 1221 Avenue of the Americas New York, New York 10020 July 14, 2020 Re: Deferred Underwriting Fee Assignment Agreement Ladies and Gentlemen: Reference is made to that certain Deferred Underwriting Fee Assignment Agreeme |
|
| August 5, 2020 |
DERMTECH, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) Exhibit 99.1 DermTech, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update LA JOLLA, Calif.-(BUSINESS WIRE)- Aug 5, 2020 - DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and unaudited financial results for the quarter ended June 30, 2020 and also pr |
|
| August 5, 2020 |
Exhibit 4.1 SEE REVERSE FOR IMPORTANT NOTICE REGARDING OWNERSHIP AND TRANSFER RESTRICTIONS AND CERTAIN OTHER INFORMATION DERMTECH, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK CUSIP 24984K 10 5 SEE REVERSE FOR CERTAIN DEFINITIONS THIS CERTIFICATE THAT IS THE OWNER OF FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK, $0.0001 PAR VALUE, OF DERMTECH, INC. (hereinafte |
|
| August 5, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated May 11, 2020 6,627,685 Shares of Common Stock This prospectus supplement No. 4 supplements the prospectus dated May 11, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc., or the Company, common stock, |
|
| August 5, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 8 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 8 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| August 5, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 5, 2020 |
Amended and Restated Certificate of Incorporation of the Company, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONSTELLATION ALPHA CAPITAL CORP. (originally incorporated on August 27, 2019 under the name Constellation Alpha Capital Corp.) FIRST: The name of the Corporation is DermTech, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Ca |
|
| June 26, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated May 11, 2020 6,627,685 Shares of Common Stock This prospectus supplement No. 3 supplements the prospectus dated May 11, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc., or the Company, common stock, |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 26, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 7 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| June 17, 2020 |
As filed with the Securities and Exchange Commission on June 17, 2020 REGISTRATION NO. |
|
| June 1, 2020 |
DMTK / DermTech, Inc. / Casdin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 27, 2020 |
DermTech, Inc. 2020 Equity Incentive Plan Exhibit 10.1 DermTech, Inc. 2020 Equity Incentive Plan 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this DermTech, Inc. 2020 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term “Administrator” |
|
| May 27, 2020 |
Exhibit 10.3 Option No. [] DERMTECH, INC. Stock Option Grant Notice Stock Option Grant under the DermTech, Inc. 2020 Equity Incentive Plan 1. Name and Address of Participant: 2. Grant Date: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesting Schedule: This Option sha |
|
| May 27, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated May 11, 2020 6,627,685 Shares of Common Stock This prospectus supplement No. 2 supplements the prospectus dated May 11, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc., or the Company, common stock, |
|
| May 27, 2020 |
Exhibit 10.4 Restricted Stock Unit No. [] DERMTECH, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the DermTech, Inc. 2020 Equity Incentive Plan 1. Name and Address of Participant: 2. Grant Date: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Particip |
|
| May 27, 2020 |
Exhibit 3.1 SECOND CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMTECH, INC. DermTech, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is DermTech, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of St |
|
| May 27, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 6 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| May 27, 2020 |
DermTech, Inc. 2020 Employee Stock Purchase Plan Exhibit 10.2 DermTech, Inc. Employee Stock Purchase Plan The following constitute the provisions of the 2020 Employee Stock Purchase Plan (the "Plan") of DermTech, Inc. (the "Company"). 1.Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company. It is the intention of the Company to have the |
|
| May 13, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 5 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| May 13, 2020 |
DERMTECH, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) Exhibit 99.1 DermTech, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update LA JOLLA, Calif.-(BUSINESS WIRE)- May 13, 2020 - DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and unaudited financial results for the quarter ended March 31, 2020 and also p |
|
| May 13, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-237991 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated May 11, 2020 6,627,685 Shares of Common Stock This prospectus supplement No. 1 supplements the prospectus dated May 11, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc., or the Company, common stock, |
|
| May 13, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 DERMTECH, INC. |
|
| May 11, 2020 |
6,627,685 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Number 333-237991 PROSPECTUS 6,627,685 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 6,627,685 shares of DermTech, Inc. |
|
| May 7, 2020 |
DERMTECH, iNC. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 May 7, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE:DermTech, Inc. Registration Statement on Form S-1 Filed May 4, 2020 File No. 333-237991 Request for Acceleration Ladies and Gentlemen: With respect to the a |
|
| May 4, 2020 |
Exhibit 10.45 DERMTECH, INC. SELLING SECURITYHOLDER NOTICE, AGREEMENT AND QUESTIONNAIRE The undersigned holder of warrants (the “Warrants”) to purchase shares of the common stock, par value $0.0001 per share, of DermTech, Inc. (“Common Stock,” and such shares of Common Stock issuable upon exercise of the Warrants, the “Warrant Shares”)1, understands that DermTech, Inc. (the “Company”) intends to f |
|
| May 4, 2020 |
Form of Placement Agent Warrant 2017 and 2018 Exhibit 4.7 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS |
|
| May 4, 2020 |
Form of Placement Agent Warrant December 2016 Exhibit 4.6 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS |
|
| May 4, 2020 |
Exhibit 4.10 OMNIBUS WARRANT AMENDMENT THIS OMNIBUS WARRANT AMENDMENT (this “Omnibus Warrant Amendment”) is made and entered into as of March 30, 2020, by and between DermTech, Inc., a Delaware corporation (the “Company”), and Paulson Investment Company, LLC (“Holder”). RECITALS WHEREAS, the Company previously issued to Holder (i) those certain warrants to purchase shares of common stock of the Co |
|
| May 4, 2020 |
Form of Omnibus Warrant Amendment for 2015 and July 2016 Placement Agent Warrants Exhibit 4.9 OMNIBUS WARRANT AMENDMENT THIS OMNIBUS WARRANT AMENDMENT (this “Omnibus Warrant Amendment”) is made and entered into as of March 30, 2020, by and between DermTech, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Schedule A hereto (the “Holders”). RECITALS WHEREAS, the Company previously issued to the Holders those certain warrants to purchase shares |
|
| May 4, 2020 |
As filed with the Securities and Exchange Commission on May 4, 2020 Registration Statement No. |
|
| April 29, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 4 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 22, 2020 |
3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com April 22, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Courtney Lindsay Celeste Murphy Re: DermTech, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 16, 2020 SEC Comment Letter dated April 21, 2020 F |
|
| April 16, 2020 |
DMTK / DermTech, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 24, 2020 |
2020 Corporate Bonus Plan of the Company Exhibit 10.2 2020 Corporate Bonus Plan 1. The DermTech, Inc. (“DermTech” or the “Company”) Corporate Bonus Plan (the “Bonus Plan”) should be simple to understand and incentivize eligible employees to achieve corporate goals which are in the best interests of stakeholders. 2. An employee must have started employment with the Company prior to October 1, 2020 to be eligible for the Bonus Plan. 3. Emp |
|
| March 24, 2020 |
9,321,593 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 3 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, comm |
|
| March 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 24, 2020 |
Offer of Employment Letter, dated September 23, 2019, from the Company to Claudia Ibarra Exhibit 10.1 John Dobak, M.D. CEO 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 Direct: 858.450.4222 Fax: 858.200.3877 www.dermtech.com September 21, 2019 Claudia Ibarra RE: OFFER OF EMPLOYMENT Dear Claudia, DermTech (the “Company”) is pleased to offer you employment as Chief Operating Officer. You will report directly to John Dobak, CEO at our facilities in San Diego, CA, subject to ne |
|
| March 11, 2020 |
9,321,593 Shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 2 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, In |
|
| March 11, 2020 |
Exhibit 4.7 DESCRIPTION OF DERMTECH, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, DermTech, Inc., had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Our Common Stock is listed on the Nasdaq C |
|
| March 11, 2020 |
Exhibit 3.2 BYLAWS OF DERMTECH, INC. TABLE OF CONTENTS Page Article I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 3 1.11 Notice of Business at Annual Meetings 6 1.12 Conduct of Meetings 8 1.13 No Action by Co |
|
| March 11, 2020 |
Amended and Restated Certificate of Incorporation of the Company, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONSTELLATION ALPHA CAPITAL CORP. (originally incorporated on August 27, 2019 under the name Constellation Alpha Capital Corp.) FIRST: The name of the Corporation is DermTech, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Ca |
|
| March 11, 2020 |
Non-Employee Director Compensation Policy, dated January 30, 2020 Exhibit 10.40 Non-Employee Director Compensation Policy DERMTECH, INC. The Board of Directors of DermTech, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, effective as of January 30, 2020 (the “Effective Time”), to provide an inducement to obtain and retain |
|
| March 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38118 DERMTECH, INC. (Exact name of registrant as |
|
| March 10, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 10, 2020 |
DERMTECH, INC. Consolidated Balance Sheets (in thousands, except share and per share data) Exhibit 99.1 DermTech, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update LA JOLLA, Calif.-(BUSINESS WIRE)- March 10, 2020 - DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results for the quarter and year ended December |
|
| March 9, 2020 |
DMTK / DermTech, Inc. / RTW INVESTMENTS, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* DERMTECH, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 24984K105 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong 412 West 15th Street, Floor 9, New York, New York 10011 (Name, Address and Telephone Number of Person Authorized |
|
| March 2, 2020 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this Agreement) is made and entered into as of March [], 2020, by and among DermTech, Inc., a Delaware corporation (the Company), and the several signatories hereto. This Agreement is made pursuant to the Securities Purchase Agreement (the Purchase Agreement), dated as of February 28, 2020 between the Comp |
|
| March 2, 2020 |
DermTech Announces $65 Million Private Placement EX-99.1 6 d873792dex991.htm EX-99.1 Exhibit 99.1 DermTech Announces $65 Million Private Placement LA JOLLA, Calif.—(BUSINESS WIRE)—March 2, 2020— DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has entered into a definitive securities purchase agreement with certain institutional investors (the |
|
| March 2, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commissi |
|
| March 2, 2020 |
9,321,593 Shares of Common Stock 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated February 10, 2020 9,321,593 Shares of Common Stock This prospectus supplement no. 1 supplements the prospectus dated February 10, 2020, or the Prospectus, relating to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company |
|
| March 2, 2020 |
EX-3.1 Exhibit 3.1 DERMTECH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John Dobak and Kevin Sun, do hereby certify that: 1. They are the President and Secretary, respectively, of DermTech, Inc., a Delaware corporation (the Corporation). 2. The Co |
|
| March 2, 2020 |
EX-3.2 Exhibit 3.2 DERMTECH, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B-2 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, John Dobak and Kevin Sun, do hereby certify that: 1. They are the President and Secretary, respectively, of DermTech, Inc., a Delaware corporation (the “Corporation”). 2. The Co |
|
| March 2, 2020 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 28, 2020 by and among DermTech, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purc |
|
| February 14, 2020 |
DMTK / DermTech, Inc. / FARALLON CAPITAL MANAGEMENT LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2020 |
9,321,593 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-235780 PROSPECTUS 9,321,593 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 9,321,593 shares of DermTech, Inc., or the Company, common stock, $0.0001 par value per share, or the Common Stock, as follows: (i) an aggregate of up to 8,565,893 shares of Common S |
|
| February 6, 2020 |
DMTK / DermTech, Inc. S-1/A - - S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 6, 2020 Registration Statement No. |
|
| February 6, 2020 |
Form of 2020 Placement Agent Warrant EX-4.6 Exhibit 4.6 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIR |
|
| February 6, 2020 |
EX-10.31 Exhibit 10.31 FIFTH AMENDMENT TO LEASE AND SIGNAGE LEASE This FIFTH AMENDMENT TO LEASE (“Fifth Amendment”) is made and entered into as of the 5th day of February, 2020 (the “Effective Date”), by and between HCP TORREY PINES, LLC, a Delaware limited liability company (“Lessor”), and DERMTECH, INC., a Delaware corporation (“Lessee”). R E C I T A L S : A. Lessor (as successor-in-interest to |
|
| February 6, 2020 |
DMTK / DermTech, Inc. CORRESP - - CORRESP DERMTECH, INC. 11099 N. Torrey Pines Road, Suite 100 La Jolla, CA 92037 February 6, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: DermTech, Inc. Registration Statement on Form S-1 Filed February 6, 2020 File No. 333-235780 Request for Acceleration Ladies and Gentlemen: With respect to the above- |
|
| January 30, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 30, 2020 |
Corporate PRESENTATION q1 2020 Exhibit 99.1 This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “continues,” “could,” “seeks,” “ |
|
| January 21, 2020 |
EX-10.2 Exhibit 10.2 Restricted Stock Unit No. DERMTECH, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE Restricted Stock Unit Award Grant under the DermTech, Inc. Amended and Restated 2010 Stock Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Units: 3. Maximum Number of Shares underlying Restricted Stock Units: 4. Vesting of Restricted Stock Units: The Restricted Stock |
|
| January 21, 2020 |
EX-99.1 INVESTOR PRESENTATION q1 2020 Exhibit 99.1 This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “continues,” “could,” “se |
|
| January 21, 2020 |
EX-10.1 Exhibit 10.1 Option No. [] DERMTECH, INC. STOCK OPTION GRANT NOTICE Stock Option Grant under the DermTech, Inc. Amended and Restated 2010 Stock Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesti |
|
| January 21, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 DERMTECH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38118 84-2870849 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 17, 2020 |
EX-99.2 Exhibit 99.2 Option No. [] DERMTECH, INC. STOCK OPTION GRANT NOTICE Stock Option Grant under the DermTech, Inc. Amended and Restated 2010 Stock Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesti |
|
| January 17, 2020 |
DMTK / DermTech, Inc. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on January 17, 2020 REGISTRATION NO. |
